NLRP3 and COVID-19: Therefore, inhibition of the NLRP3 inflammasome could potentially lead to a corresponding decrease in the levels of strongly pro-inflammatory cytokines, especially IL-1β, which is released from pyroptotic macrophages and monocytes in large amounts in COVID-19 ARDS [23,51,69,70].